Results 111 to 120 of about 14,163 (275)
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background The gut‐derived hormone GLP‐1 (glucagon‐like peptide‐1) exerts beneficial effects against established risk factors for chronic kidney disease.
Xuefei Liu, Kaushik P. Patel, Hong Zheng
doaj +1 more source
Degradation of islet amyloid polypeptide by neprilysin [PDF]
Diabetologia, 2012 A progressive loss of pancreatic beta cell function, a decrease in beta cell mass and accumulation of islet amyloid is characteristic of type 2 diabetes mellitus. The main constituent of islet amyloid is islet amyloid polypeptide (IAPP). In this study, we examined the ability of the peptidase neprilysin to cleave IAPP and prevent human IAPP-induced ...
K. M. Chow +4 more
openaire +2 more sources
ESC Heart Failure, EarlyView.Abstract Aims Atrial fibrillation (AF) is a frequent comorbidity in heart failure (HF). We analysed factors associated with new‐onset atrial fibrillation in patients with heart failure using linked real‐world UK data from primary and secondary care, along with findings from genome‐wide association studies. Methods and results Among 163 174 participants
Hiroyuki Yoshimura +6 more
wiley +1 more source
Association between soluble neprilysin and diabetes: Findings from a prospective longitudinal study
Frontiers in Endocrinology, 2023 BackgroundThe potential role of neprilysin (NEP) in glucose metabolism has been found by basic studies but lacks population evidence. The objective of this study was to examine the association between serum NEP and diabetes in Chinese adults.MethodsIn a ...
Junting Hu +10 more
doaj +1 more source
ESC Heart Failure, EarlyView.Asymptomatic reduced left ventricular ejection fraction (LVEF) in the acute phase of myocardial infarction (AMI) was associated with up to 20% 1‐year mortality after discharge, substantially higher than in recent post‐MI trials. Symptoms of heart failure (HF) during the index hospitalization was associated with worse outcomes in patients with preserved
Jarle Jortveit +3 more
wiley +1 more source
Potential of valsartan+sacubitril therapy in hypertensive heart disease
Российский кардиологический журнал, 2021 The course of hypertension is often complicated by left ventricular hypertrophy (or hypertensive heart disease, HHD). The main “corridor” of natural HHD is development of heart failure with preserved ejection fraction (HFpEF).
A. G. Ovchinnikov +4 more
doaj +1 more source
Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]
, 2017 Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T. +11 more
core +3 more sources
Circulation: Heart Failure, 2021 Supplemental Digital Content is available in the text. Background: Sacubitril/valsartan (S/V) treatment is associated with reverse cardiac remodeling and reductions in biomarkers reflecting ventricular wall stress and myocardial injury, such as NT-proBNP
Sean P. Murphy +11 more
semanticscholar +1 more source
ESC Heart Failure, EarlyView.The H2‐Registry: overview, first results and outlook. Abstract Aims Heart failure (HF) is a highly prevalent condition affecting 1–3% of the adult population in Europe. Despite landmark improvements in HF care over the last two decades, hospitalization and mortality rates remain relatively high.
Johannes Leiner +15 more
wiley +1 more source
What can we learn from SOCRATES: more questions than answers? [PDF]
, 2017 This editorial refers to ‘Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) Study’, by B ...
Cleland, John G.F., Mueller, Christian
core +1 more source